Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$650.06 USD

650.06
798,784

+25.87 (4.14%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $650.31 +0.25 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.

Zacks Equity Research

Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better

by Zacks Equity Research

Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.

Zacks Equity Research

IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches

by Zacks Equity Research

Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.

Zacks Equity Research

Masimo's Latest Buyout to Boost Respiratory Product Spectrum

by Zacks Equity Research

Masimo (MASI) expects the transaction to be neutral to 2020 earnings.

Zacks Equity Research

Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

by Zacks Equity Research

Baxter (BAX) issues strong guidance for the first quarter of 2020.

Zacks Equity Research

Varian's (VAR) ProBeam Compact Treats First Patient at UAB

by Zacks Equity Research

Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.

Zacks Equity Research

Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.

Zacks Equity Research

Here's Why You Should Hold Onto Varian Medical Stock Now

by Zacks Equity Research

Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.

Zacks Equity Research

Here's Why You Should Buy Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.

Zacks Equity Research

Cooper Companies (COO) Misses on Q1 Earnings, Lifts View

by Zacks Equity Research

Cooper Companies (COO) gains from core CVI segment in fiscal Q1.

Nalak Das headshot

5 Must-Buy S&P 500 Large-Cap Growth Stocks at a Discount

by Nalak Das

As a result of regular market fluctuations, several growth stocks have become ultra-cheap at present, some of which have strong growth potential.

Zacks Equity Research

Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.

Zacks Equity Research

Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.

Zacks Equity Research

Here's Why You Should Hold Avanos Medical (AVNS) Stock Now

by Zacks Equity Research

Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.

Zacks Equity Research

What's in Store for Cooper Companies (COO) Q1 Earnings?

by Zacks Equity Research

Cooper Companies (COO) fiscal first-quarter performance is likely to reflect better-than-expected performance at CVI and CSI, and higher revenues.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings Lag Estimates, Sales Rise

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) gains from the Technologies & Equipment arm in Q4.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

Zacks Equity Research

Why Is Idexx (IDXX) Down 10.3% Since Last Earnings Report?

by Zacks Equity Research

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Teladoc (TDOC) Hits New 52-Week High on Strong Q4 Results

by Zacks Equity Research

Teladoc (TDOC) reaches new 52-week high in the trading session on Feb 27 on impressive fourth-quarter results.

Zacks Equity Research

Avanos (AVNS) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Avanos (AVNS) gains from segmental contributions in Q4.

Zacks Equity Research

OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales Up

by Zacks Equity Research

OPKO (OPK) gains from increase in RAYALDEE prescriptions.

Zacks Equity Research

LHC Group (LHCG) Q4 Earnings Meet Estimates, Revenues Lag

by Zacks Equity Research

LHC Group (LHCG) fourth-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results benefit from higher revenues and solid show by Dental as well as Animal Health segments.